Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice
详细信息 查看全文
- 作者：Qiu Xia ; Fei Geng ; Fang-Fang Zhang ; Chen-Lu Liu ; Ping Xu ; Zhen-Zhen Lu ; Hai-Hong Zhang ; Zhanghh@jlu.edu.cn" class="auth_mail" title="E-mail the corresponding author ; Wei Kong ; Xiang-Hui Yu
- 关键词：Fibroblast activation protein α ; Interleukin-10 ; Cyclophosphamide ; Prime-boost strategy ; Immunosuppression ; Cancer vaccine
- 刊名：Vaccine
- 出版年：2016
- 出版时间：31 August 2016
- 年：2016
- 卷：34
- 期：38
- 页码：4526-4535
- 全文大小：2436 K
文摘
Fibroblast activation protein α (FAPα) is expressed in cancer-associated fibroblasts (CAFs) of more than 90% of malignant epithelia carcinomas. CAFs are the main type of cells in the tumor microenvironment which offer nutrition and protection to the tumor and regulate immunosuppression. To eliminate CAFs, a vaccine targeting FAPα may be used with a heterologous prime-boost strategy to enhance the FAPα-specific cellular immunity. Here, a FAP vaccine using a recombinant adenovirus (rAd) vector was constructed as well as a DNA vaccine reported in our previous work. Although the DNA prime-rAd boost strategy enhanced FAPα-specific immune responses, improvement of anti-tumor immunity effects was not observed. Examination of immunosuppressive factors revealed that high expression of the IL-10 cytokine was considered the main cause of the failure of the prime-boost strategy. However, heterologous vaccination in combination with a low-dose of cyclophosphamide (CY), which was reported to reduce IL-10 production and promote a shift from immunosuppression to immunopotentiation, resulted in enhanced effects in terms of numbers of effector T cells and tumor growth inhibition rates, compared to the CY alone or DNA alone group. Tumor growth was inhibited markedly when the prime-boost strategy was combined with CY in both the prophylactic and therapeutic settings and the survival time of 4T1 tumor bearing mice was also prolonged significantly. With the reduction of IL-10, enhancement of the anti-tumor effect by the prime-boost strategy was observed. These results suggest that FAPα-targeted rAd boosting in combination with CY is an attractive approach to overcoming immunosuppression in cancer vaccines.